Impact on the links of the mastopathy pathogenesis: a view on the pathological cascade correction

Abstract

Background. Dyshormonal diseases of the breast (DDB) are a mirror of gynecological problems and pathological conditions of the thyroid gland (TG). The herbal non-hormonal drug Tazalok, which has hormone-regulating, anti-estrogenic, anti-proliferative, anti-inflammatory, sedative and tonic effects, was chosen as a drug for the treatment of various clinical and morphological forms of DDB. Objectives of the study: to investigate the possibilities of optimizing the DDB treatment and to evaluate the effectiveness of phytoselective therapy with Tazalok on various pathogenic links of mastopathy, taking into account the role of the TG in the pathogenesis of DDB. Materials and methods. The study included 140 women of reproductive age with DDB, who were divided into 4 groups depending on the morphological forms of DDB, 35 women in each: I group – fibrocystic mastopathy; group II – the predominance of the cystic component, solitary cysts of the breast; III group – predominance of the fibrous component, with expansion of the milk ducts; group IV – mastodynia without organic changes in the breast. Patients received Tazalok 45 drops twice a day for 3 months. The level of sex steroids and thyroid hormones was determined before and after treatment, an ultrasound of the breast and TG was performed, and the dynamics of the pain syndrome were evaluated using a color analog scale. Results. A decrease in the level of estradiol to reference norms, an increase in follicle-stimulating and luteinizing hormones, progesterone, elimination of insufficiency of the luteal phase and restoration of ovulation were noted. The ratio of estradiol/progesterone in the study groups before the start of therapy was 1.6–4.5, after treatment it was 0.12–0.08, which indicates the disappearance of hyperestrogeny, as one of the main factors of DDB. The level of prolactin decreased from 1.6 to 2.0 times compare to the indicators before therapy. Thyroid function indicators improved, morphological signs of pathological changes in the TG and breast decreased, and the level of hormones normalized. Conclusions. Monotherapy with Tazalok is a highly effective method of treating DDB, which results in functional and organic changes in the breast, TG, reduction of pain syndrome and echographic signs of the disease.

Keywords

• dyshormonal diseases of breast
• thyroid gland
• mammary gland
• treatment
• tazalok